Nilsson, M. B., Giri, U., Gudikote, J., Tang, X., Lu, W., Tran, H., . . . Heymach, J. V. (2015). KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res.

Nilsson, Monique B., et al. "KDR Amplification Is Associated With VEGF-Induced Activation of the MTOR and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib." Clin Cancer Res 2015.

Nilsson, Monique B., et al. "KDR Amplification Is Associated With VEGF-Induced Activation of the MTOR and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib." Clin Cancer Res 2015.